Cancer patient told she will get drug which could make her life longer

• Sacituzumab govitecan is now available on the NHS for patients with incurable (metastatic triple-negative) breast cancer, following a revised cost-effectiveness assessment after initial rejection.
• The drug has demonstrated ability to extend survival in advanced breast cancer patients, representing a significant treatment option previously unavailable through routine NHS provision.
• This decision reverses a prior funding decision, highlighting how continued negotiations and evidence review can lead to access for treatments initially considered too costly by health technology assessment bodies.

Patients in England with an incurable breast cancer can now access a life-extending drug on the NHS, two years after it was deemed too expensive by a health body.

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.